FOLD logo

Amicus Therapeutics, Inc. (FOLD) Cash From Financing

Annual CFF:

$5.12M-$56.56M(-91.70%)
December 31, 2024

Summary

  • As of today, FOLD annual cash from financing is $5.12 million, with the most recent change of -$56.56 million (-91.70%) on December 31, 2024.
  • During the last 3 years, FOLD annual cash from financing has fallen by -$206.95 million (-97.59%).
  • FOLD annual cash from financing is now -98.86% below its all-time high of $450.77 million, reached on December 31, 2018.

Performance

FOLD Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherFOLDcash flow metrics

Quarterly CFF:

-$400.00K+$11.30M(+96.58%)
June 30, 2025

Summary

  • As of today, FOLD quarterly cash from financing is -$400.00 thousand, with the most recent change of +$11.30 million (+96.58%) on June 30, 2025.
  • Over the past year, FOLD quarterly cash from financing has increased by +$457.00 thousand (+53.33%).
  • FOLD quarterly cash from financing is now -100.13% below its all-time high of $296.58 million, reached on March 31, 2018.

Performance

FOLD Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherFOLDcash flow metrics

TTM CFF:

$7.19M+$457.00K(+6.79%)
June 30, 2025

Summary

  • As of today, FOLD TTM cash from financing is $7.19 million, with the most recent change of +$457.00 thousand (+6.79%) on June 30, 2025.
  • Over the past year, FOLD TTM cash from financing has dropped by -$24.48 million (-77.30%).
  • FOLD TTM cash from financing is now -98.72% below its all-time high of $560.64 million, reached on June 30, 2018.

Performance

FOLD TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherFOLDcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

FOLD Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-91.7%+53.3%-77.3%
3Y3 Years-97.6%-157.7%-96.3%
5Y5 Years-97.7%-109.8%-97.1%

FOLD Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-97.6%+168.6%-101.1%+97.0%-88.3%+188.5%
5Y5-Year-98.0%+168.6%-100.2%+97.0%-97.4%+188.5%
All-TimeAll-Time-98.9%+168.6%-100.1%+97.0%-98.7%+188.5%

FOLD Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2025
-
-$400.00K(+96.6%)
$7.19M(+6.8%)
Mar 2025
-
-$11.70M(-1166.5%)
$6.73M(+31.4%)
Dec 2024
$5.12M(-91.7%)
$1.10M(-94.0%)
$5.12M(-58.1%)
Sep 2024
-
$18.19M(+2222.5%)
$12.23M(-61.4%)
Jun 2024
-
-$857.00K(+93.6%)
$31.66M(-43.7%)
Mar 2024
-
-$13.31M(-262.1%)
$56.19M(-8.9%)
Dec 2023
$61.68M(+926.4%)
$8.21M(-78.2%)
$61.68M(+14.2%)
Sep 2023
-
$37.62M(+58.9%)
$54.02M(+240.9%)
Jun 2023
-
$23.67M(+402.5%)
$15.85M(+322.1%)
Mar 2023
-
-$7.83M(-1504.8%)
-$7.13M(+4.4%)
Dec 2022
-$7.46M(-103.5%)
$557.00K(+199.6%)
-$7.46M(+8.1%)
Sep 2022
-
-$559.00K(-180.7%)
-$8.12M(-104.2%)
Jun 2022
-
$693.00K(+108.5%)
$193.55M(-0.8%)
Mar 2022
-
-$8.15M(-7740.4%)
$195.09M(-8.0%)
Dec 2021
$212.07M(-19.3%)
-$104.00K(-100.1%)
$212.07M(-9.3%)
Sep 2021
-
$201.11M(+8898.3%)
$233.72M(-13.9%)
Jun 2021
-
$2.23M(-74.7%)
$271.32M(-0.7%)
Mar 2021
-
$8.83M(-59.0%)
$273.17M(+3.9%)
Dec 2020
$262.86M(+20.9%)
$21.55M(-91.0%)
$262.86M(+7.5%)
Sep 2020
-
$238.71M(+5742.2%)
$244.50M(+3773.0%)
Jun 2020
-
$4.09M(+374.8%)
$6.31M(-96.8%)
Mar 2020
-
-$1.49M(-146.6%)
$198.63M(-8.7%)
Dec 2019
$217.50M(-51.7%)
$3.19M(+510.1%)
$217.50M(+1.3%)
Sep 2019
-
$523.00K(-99.7%)
$214.67M(-40.5%)
Jun 2019
-
$196.40M(+1029.8%)
$360.95M(+110.4%)
Mar 2019
-
$17.38M(+4742.3%)
$171.58M(-61.9%)
Dec 2018
$450.77M(+82.2%)
$359.00K(-99.8%)
$450.77M(-1.4%)
Sep 2018
-
$146.80M(+1987.4%)
$457.25M(-18.4%)
Jun 2018
-
$7.03M(-97.6%)
$560.64M(+3.0%)
Mar 2018
-
$296.58M(+4238.5%)
$544.08M(+119.9%)
Dec 2017
$247.43M(-9.3%)
$6.84M(-97.3%)
$247.43M(-36.7%)
Sep 2017
-
$250.19M(+2726.9%)
$390.92M(+116.7%)
Jun 2017
-
-$9.52M(>-9900.0%)
$180.36M(-34.0%)
Mar 2017
-
-$67.00K(-100.0%)
$273.15M(+0.2%)
Dec 2016
$272.71M(-6.2%)
$150.32M(+279.3%)
$272.71M(+122.5%)
Sep 2016
-
$39.63M(-52.4%)
$122.55M(-10.2%)
Jun 2016
-
$83.26M(>+9900.0%)
$136.41M(-52.4%)
Mar 2016
-
-$502.00K(-432.5%)
$286.33M(-1.6%)
Dec 2015
$290.89M
$151.00K(-99.7%)
$290.89M(-25.3%)
DateAnnualQuarterlyTTM
Sep 2015
-
$53.50M(-77.1%)
$389.39M(+8.7%)
Jun 2015
-
$233.18M(+5639.0%)
$358.25M(+150.0%)
Mar 2015
-
$4.06M(-95.9%)
$143.33M(+3.0%)
Dec 2014
$139.18M(+373.7%)
$98.64M(+341.1%)
$139.18M(+98.2%)
Sep 2014
-
$22.36M(+22.5%)
$70.21M(+47.0%)
Jun 2014
-
$18.25M(>+9900.0%)
$47.75M(+62.4%)
Mar 2014
-
-$85.00K(-100.3%)
$29.39M(+0.1%)
Dec 2013
$29.38M(-63.9%)
$29.68M(>+9900.0%)
$29.38M(>+9900.0%)
Sep 2013
-
-$100.00K(-1.0%)
$162.00K(-99.1%)
Jun 2013
-
-$99.00K(+1.0%)
$18.11M(+1.8%)
Mar 2013
-
-$100.00K(-121.7%)
$17.80M(-78.2%)
Dec 2012
$81.48M(+8823.6%)
$461.00K(-97.4%)
$81.48M(+1.0%)
Sep 2012
-
$17.85M(+4391.1%)
$80.70M(+29.0%)
Jun 2012
-
-$416.00K(-100.7%)
$62.55M(-0.7%)
Mar 2012
-
$63.58M(>+9900.0%)
$62.97M(+6842.1%)
Dec 2011
-$934.00K(-102.1%)
-$313.00K(-3.3%)
-$934.00K(-103.4%)
Sep 2011
-
-$303.00K(-6160.0%)
$27.11M(+0.3%)
Jun 2011
-
$5000.00(+101.5%)
$27.04M(+1.7%)
Mar 2011
-
-$323.00K(-101.2%)
$26.59M(-39.1%)
Dec 2010
$43.66M(+1476.7%)
$27.73M(+7553.5%)
$43.66M(+179.8%)
Sep 2010
-
-$372.00K(+16.6%)
$15.60M(-6.2%)
Jun 2010
-
-$446.00K(-102.7%)
$16.63M(-15.9%)
Mar 2010
-
$16.75M(+5222.0%)
$19.78M(+614.3%)
Dec 2009
$2.77M(+377.5%)
-$327.00K(-149.8%)
$2.77M(-1.2%)
Sep 2009
-
$657.00K(-75.7%)
$2.80M(+45.3%)
Jun 2009
-
$2.70M(+1130.9%)
$1.93M(+271.1%)
Mar 2009
-
-$262.00K(+10.9%)
-$1.13M(-12.9%)
Dec 2008
-$998.00K(-101.1%)
-$294.00K(-35.5%)
-$998.00K(-0.3%)
Sep 2008
-
-$217.00K(+38.7%)
-$995.00K(+3.4%)
Jun 2008
-
-$354.00K(-166.2%)
-$1.03M(-101.5%)
Mar 2008
-
-$133.00K(+54.3%)
$67.83M(-26.2%)
Dec 2007
$91.91M(+38.9%)
-$291.00K(-15.5%)
$91.91M(-0.3%)
Sep 2007
-
-$252.00K(-100.4%)
$92.20M(-0.3%)
Jun 2007
-
$68.51M(+186.1%)
$92.45M(+286.1%)
Mar 2007
-
$23.94M
$23.94M
Dec 2006
$66.17M(+60.4%)
-
-
Dec 2005
$41.25M(+196.7%)
-
-
Dec 2004
$13.91M(+281.2%)
-
-
Dec 2003
$3.65M
-
-

FAQ

  • What is Amicus Therapeutics, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Amicus Therapeutics, Inc.?
  • What is Amicus Therapeutics, Inc. annual cash from financing year-on-year change?
  • What is Amicus Therapeutics, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Amicus Therapeutics, Inc.?
  • What is Amicus Therapeutics, Inc. quarterly cash from financing year-on-year change?
  • What is Amicus Therapeutics, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Amicus Therapeutics, Inc.?
  • What is Amicus Therapeutics, Inc. TTM cash from financing year-on-year change?

What is Amicus Therapeutics, Inc. annual cash from financing?

The current annual cash from financing of FOLD is $5.12M

What is the all-time high annual cash from financing for Amicus Therapeutics, Inc.?

Amicus Therapeutics, Inc. all-time high annual cash from financing is $450.77M

What is Amicus Therapeutics, Inc. annual cash from financing year-on-year change?

Over the past year, FOLD annual cash from financing has changed by -$56.56M (-91.70%)

What is Amicus Therapeutics, Inc. quarterly cash from financing?

The current quarterly cash from financing of FOLD is -$400.00K

What is the all-time high quarterly cash from financing for Amicus Therapeutics, Inc.?

Amicus Therapeutics, Inc. all-time high quarterly cash from financing is $296.58M

What is Amicus Therapeutics, Inc. quarterly cash from financing year-on-year change?

Over the past year, FOLD quarterly cash from financing has changed by +$457.00K (+53.33%)

What is Amicus Therapeutics, Inc. TTM cash from financing?

The current TTM cash from financing of FOLD is $7.19M

What is the all-time high TTM cash from financing for Amicus Therapeutics, Inc.?

Amicus Therapeutics, Inc. all-time high TTM cash from financing is $560.64M

What is Amicus Therapeutics, Inc. TTM cash from financing year-on-year change?

Over the past year, FOLD TTM cash from financing has changed by -$24.48M (-77.30%)
On this page